ライフサイエンスコーパス: erenumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 placebo (n=286), erenumab 70 mg (n=191), or erenumab 140 mg (n=190).

2 to subcutaneous placebo, erenumab 70 mg, or erenumab 140 mg, given every 4 weeks for 12 weeks.

3 andomly assigned to receive placebo (n=286), erenumab 70 mg (n=191), or erenumab 140 mg (n=190).

4 Erenumab 70 mg and 140 mg reduced monthly migraine days

5 RETATION: In patients with chronic migraine, erenumab 70 mg and 140 mg reduced the number of monthly

6 ly assigned (3:2:2) to subcutaneous placebo, erenumab 70 mg, or erenumab 140 mg, given every 4 weeks

7 We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the

8 We tested erenumab, a fully human monoclonal antibody that inhibit

9 Erenumab administered subcutaneously at a monthly dose o

10 rates of adverse events were similar between erenumab and placebo.

11 understand long-term efficacy and safety of erenumab, and the applicability of this study to real-wo

12 cal laboratory values, vital signs, and anti-erenumab antibodies.

13 o receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo month

14 group and three in the 140 mg group had anti-erenumab binding antibodies; none had anti-erenumab neut

15 similar to placebo, providing evidence that erenumab could be a potential therapy for migraine preve

16 nd, placebo-controlled, multicentre study of erenumab for adults aged 18-65 years with chronic migrai

17 achieved for 43.3% of patients in the 70-mg erenumab group and 50.0% of patients in the 140-mg erenu

18 ication was reduced by 1.1 days in the 70-mg erenumab group and by 1.6 days in the 140-mg erenumab gr

19 mber of days was reduced by 3.2 in the 70-mg erenumab group and by 3.7 in the 140-mg erenumab group,

20 andomization: 317 were assigned to the 70-mg erenumab group, 319 to the 140-mg erenumab group, and 31

21 the 70-mg erenumab group, 319 to the 140-mg erenumab group, and 319 to the placebo group.

22 erenumab group and by 1.6 days in the 140-mg erenumab group, as compared with 0.2 days in the placebo

23 0-mg erenumab group and by 3.7 in the 140-mg erenumab group, as compared with 1.8 days in the placebo

24 ab group and 50.0% of patients in the 140-mg erenumab group, as compared with 26.6% in the placebo gr

25 y 4.2 and 4.8 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 2.4 poin

26 y 5.5 and 5.9 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 3.3 poin

27 i-erenumab binding antibodies; none had anti-erenumab neutralising antibodies.

28 -term safety and durability of the effect of erenumab require further study.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。